Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Tagitanlimab in AVPC/NEPC
NCT07179783Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, tagitanlimab in prostate cancer (PCa), neuroendocrine prostate cancer (NEPC), sponsored by The Second Hospital of Tianjin Medical University. Started Sep 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
prostate cancer (PCa)neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT07179783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179783.